Medicenna Therapeutics Corp. Trading Income Expense On Derivative Financial Instruments
Medicenna Therapeutics Corp. (MDNAF) reported Trading Income Expense On Derivative Financial Instruments of -CAD 652.00 thousand for the 12-month period ending 2023-03-31, per its 20-F filed 2023-06-27.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:TradingIncomeExpenseOnDerivativeFinancialInstruments · last filed 2023-06-27
| Period end | Trading Income Expense On Derivative Financial Instruments 12 month |
|---|---|
| 2023-03-31 | -652.00K CAD 20-F · filed 2023-06-27 |
| 2022-03-31 | 0.00 CAD 20-F · filed 2023-06-27 |
| 2021-03-31 | 0.00 CAD 20-F · filed 2023-06-27 |